Abbott Laboratories (NYSE:ABT) price target raised to $93.00 by Morgan Stanley

ME Staff
-
0

Analyst Ratings For Abbott Laboratories (NYSE:ABT)

Today, Morgan Stanley raised its price target on Abbott Laboratories (NYSE:ABT) to $93.00 per share.

There are 14 Buy Ratings, 3 Hold Ratings, 1 Sell Ratings, no Strong Buy Ratings on the stock.

The current consensus rating on Abbott Laboratories (NYSE:ABT) is Buy with a consensus target price of $81.74 per share, a potential 1.61% downside.

Some recent analyst ratings include

  • 6/13/2019-Abbott Laboratories (NYSE:ABT) had its Buy rating reiterated by Bank of America with a $81.00 price target
  • 4/18/2019-Abbott Laboratories (NYSE:ABT) had its Outperform rating reiterated by William Blair
  • On 6/26/2019 Daniel Gesua Sive Salvadori, EVP, sold 71,000 with an average share price of $84.00 per share and the total transaction amounting to $5,964,000.00.
  • On 6/20/2019 Hubert L Allen, Insider, sold 165,000 with an average share price of $85.00 per share and the total transaction amounting to $14,025,000.00.
  • On 6/20/2019 John M Capek, EVP, sold 46,900 with an average share price of $85.00 per share and the total transaction amounting to $3,986,500.00.
  • On 6/13/2019 Daniel Gesua Sive Salvadori, Insider, sold 10,600 with an average share price of $82.00 per share and the total transaction amounting to $869,200.00.
  • On 6/11/2019 Daniel Gesua Sive Salvadori, EVP, sold 7,269 with an average share price of $82.00 per share and the total transaction amounting to $596,058.00.
  • On 5/23/2019 Brian J Blaser, Insider, sold 450,062 with an average share price of $75.52 per share and the total transaction amounting to $33,988,682.24.
  • On 5/2/2019 Jared Watkin, Insider, sold 309,429 with an average share price of $78.51 per share and the total transaction amounting to $24,293,270.79.

About Abbott Laboratories (NYSE:ABT)
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Read More…

Recent Trading Activity for Abbott Laboratories (NYSE:ABT)
Shares of Abbott Laboratories closed the previous trading session at 83.26 −0.56 0.67% with 84.11 shares trading hands.